Indicators
Indicators
Value
Direction
MACD(12,26,9)
-7.083
Neutral
RSI(14)
50.070
Neutral
STOCH(KDJ)(9,3,3)
25.930
Buy
ATR(14)
7.358
Low Volatility
CCI(14)
-49.321
Neutral
Williams %R
61.980
Sell
TRIX(12,20)
0.044
Sell
StochRSI(14)
100.000
Buy
Amgen Inc
AMGN325.340USD
+7.600+2.39%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
175.20BMarket Cap
24.98P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Amgen Inc
Currency: USD Updated: 2025-12-12Key Insights
Amgen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 45/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 326.54.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amgen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
35
analysts
Buy
Current Rating
326.535
Target Price
+1.65%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Amgen Inc Highlights
StrengthsRisks
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.98% year-on-year.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 120.56%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 120.56%.
Fairly Valued
The company’s latest PE is 24.40, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 451.47M shares, increasing 0.01% quarter-over-quarter.
Held by Ray Dalio
Star Investor Ray Dalio holds 11.29K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-12The current financial score of Amgen Inc is 8.78, ranking 36/159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 9.56B, representing a year-over-year increase of 12.40%, while its net profit experienced a year-over-year increase of 13.64%.
Score
Financials
6.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.76
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
9.11
Amgen Inc's Company Valuation
Currency: USD Updated: 2025-12-12The current valuation score of Amgen Inc is 7.15, ranking 96/159 in the Pharmaceuticals industry. Its current P/E ratio is 24.40, which is 137.13% below the recent high of 57.86 and 40.68% above the recent low of 14.47.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 45/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-12The current earnings forecast score of Amgen Inc is 7.03, ranking 117/159 in the Pharmaceuticals industry. The average price target for Amgen Inc is 323.50, with a high of 400.00 and a low of 180.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
35
analysts
Buy
Current Rating
326.535
Target Price
+1.65%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Amgen Inc
AMGN
35
Biogen Inc
BIIB
36
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
Gilead Sciences Inc
GILD
31
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-12The current price momentum score of Amgen Inc is 6.89, ranking 99/159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 338.62 and the support level at 304.62, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
317.932
Buy
MA10
326.472
Sell
MA20
333.468
Sell
MA50
315.754
Buy
MA100
301.736
Buy
MA200
297.039
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-12The current institutional shareholding score of Amgen Inc is 7.00, ranking 44/159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 85.20%, representing a quarter-over-quarter decrease of 0.10%. The largest institutional shareholder is The Vanguard, holding a total of 53.62M shares, representing 9.96% of shares outstanding, with 1.73% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
Capital International Investors
Capital World Investors
Charles Schwab Investment Management, Inc.
Geode Capital Management, L.L.C.
Invesco Capital Management (QQQ Trust)
Morgan Stanley Smith Barney LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-12The current risk assessment score of Amgen Inc is 9.37, ranking 13/159 in the Pharmaceuticals industry. The company's beta value is 0.45. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.45
VaR
+2.06%
240-Day Maximum Drawdown
+19.88%
240-Day Volatility
+27.07%
Return
Best Daily Return
60 days
+7.81%
120 days
+7.81%
5 years
+11.82%
Worst Daily Return
60 days
-3.02%
120 days
-5.14%
5 years
-7.22%
Sharpe Ratio
60 days
+2.12
120 days
+1.31
5 years
+0.56
Risk Assessment
Maximum Drawdown
240 days
+19.88%
3 years
+23.35%
5 years
+26.72%
Return-to-Drawdown Ratio
240 days
+1.06
3 years
+0.37
5 years
+0.30
Skewness
240 days
+0.31
3 years
+0.48
5 years
+0.37
Volatility
Realised Volatility
240 days
+27.07%
5 years
+24.83%
Standardised True Range
240 days
+2.23%
5 years
+1.76%
Downside Risk-Adjusted Return
120 days
+235.91%
240 days
+235.91%
Maximum Daily Upside Volatility
60 days
+25.09%
Maximum Daily Downside Volatility
60 days
+15.55%
Liquidity
Average Turnover Rate
60 days
+0.42%
120 days
+0.50%
5 years
--
Turnover Deviation
20 days
-23.89%
60 days
-17.09%
120 days
-1.46%
Peer Comparison
Pharmaceuticals
Amgen Inc
AMGN
7.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.88 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Amgen Inc?
The TradingKey Stock Score provides a comprehensive assessment of Amgen Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Amgen Inc’s performance and outlook.
How do we generate the financial health score of Amgen Inc?
To generate the financial health score of Amgen Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Amgen Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Amgen Inc.
How do we generate the company valuation score of Amgen Inc?
To generate the company valuation score of Amgen Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Amgen Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Amgen Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Amgen Inc.
How do we generate the earnings forecast score of Amgen Inc?
To calculate the earnings forecast score of Amgen Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Amgen Inc’s future.
How do we generate the price momentum score of Amgen Inc?
When generating the price momentum score for Amgen Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Amgen Inc’s prices. A higher score indicates a more stable short-term price trend for Amgen Inc.
How do we generate the institutional confidence score of Amgen Inc?
To generate the institutional confidence score of Amgen Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Amgen Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Amgen Inc.
How do we generate the risk management score of Amgen Inc?
To assess the risk management score of Amgen Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Amgen Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Amgen Inc.
